阿卡替尼 Acalabrutinib Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
康奈非尼 Encorafenib Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
達(dá)帕菲尼 Dabrafenib Dabrafenib, also known as GSK2118436 , is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
維羅非尼 Vemurafenib Also known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
普納替尼 Ponatinib Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商